2M.D. Asistant, Sisli Etfal Training and Rsearch Hospital, Eye Clinic, Istanbul/TURKEY
3M.D. Associate Professor, Sisli Etfal Training and Rsearch Hospital, Eye Clinic, Istanbul/TURKEY Purpose: To compare of results the outcomes of best corrected visual acuity(BCVA) and central macular thickness (CMT) in phakic and pseudophakic eyes after intravitreal ranibizumab injection for diffuse diabetic macular edema.
Materials and Methods: This retrospective study included 46 eyes with diffuse diabetic macular edema (DME), which had no history treatment for diabetic macular edema, received 3 injections of ranibizumaab with one month intervals. All patients had type 2 diabetes mellitus with nonproliferative diabetic retinopathy and diffuse DME which had no history of treatment. Detailed eye examination included measurement of BCVA, intraocular pressure (IOP) and CMT using optical coherence tomography(OCT) was performed in all patients. BCVA, CMT and IOP were compared between the two groups. A p<0.05 was considered statistically significant.
Results: There were 24 eyes in phakic group and there were 22 eyes in pseudophakic group. Mean age was 59.5±9.2 and 66.3±10.8 years old in the phakic and pseudophakic group, respectively. Baseline BCVA was 0.36±0.24 in phakic and 0.28±0.25 in pseudophakic group. Postoperatively, mean BCVA was 0.64±0.28 and 0.60±0.37 in the phakic and pseudophakic group, respectively. Baseline CMT was 373±97 in phakic group, and 416± 91 μm in pseudophakic group. Postoperative mean CMT was 286±76 in the phakic group and 298±102 μm in the pseudophakic group. Retinal detachment, endopthalmitis and systemic side events.
Conclusion: Three doses of intravitreal ranibizumab was effective in phakic and pseudophakic eyes with diffuse DME. The values of phakic group were better than pseudophakic group but not significant.
Keywords : Diabetic macular edema, phakic, pseudophakic, ranibizumab